Orbimed Advisors LLC Has $34.93 Million Stock Position in uniQure N.V. $QURE

Orbimed Advisors LLC boosted its position in shares of uniQure N.V. (NASDAQ:QURE) by 189.7% in the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 2,136,149 shares of the biotechnology company’s stock after purchasing an additional 1,398,749 shares during the period. Orbimed Advisors LLC’s holdings in uniQure were worth $34,926,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Rangeley Capital LLC grew its stake in uniQure by 52.9% during the first quarter. Rangeley Capital LLC now owns 13,000 shares of the biotechnology company’s stock worth $213,000 after buying an additional 4,500 shares during the last quarter. Senvest Management LLC increased its holdings in shares of uniQure by 44.6% during the first quarter. Senvest Management LLC now owns 72,300 shares of the biotechnology company’s stock worth $1,182,000 after buying an additional 22,300 shares in the last quarter. Siren L.L.C. bought a new position in shares of uniQure in the first quarter valued at approximately $16,350,000. Militia Capital Management LLC bought a new position in shares of uniQure in the first quarter valued at approximately $1,540,000. Finally, Sigma Planning Corp acquired a new position in shares of uniQure in the 1st quarter worth approximately $276,000. 78.83% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of research firms recently commented on QURE. Cantor Fitzgerald upgraded uniQure from a “neutral” rating to an “overweight” rating and set a $61.00 price target on the stock in a research report on Wednesday, June 17th. HC Wainwright lifted their price objective on uniQure from $50.00 to $80.00 and gave the company a “buy” rating in a research report on Monday, June 29th. Stifel Nicolaus set a $28.00 price objective on uniQure in a research note on Tuesday, May 5th. Barclays upgraded uniQure from an “equal weight” rating to an “overweight” rating and increased their target price for the stock from $25.00 to $65.00 in a report on Thursday, June 18th. Finally, Leerink Partners raised their target price on uniQure from $36.00 to $70.00 and gave the company an “outperform” rating in a research note on Thursday, June 18th. Twelve equities research analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, uniQure presently has an average rating of “Moderate Buy” and an average target price of $64.17.

Insider Transactions at uniQure

In other uniQure news, insider Walid Abi-Saab sold 45,000 shares of the stock in a transaction on Friday, May 8th. The stock was sold at an average price of $25.06, for a total value of $1,127,700.00. Following the transaction, the insider directly owned 169,669 shares in the company, valued at approximately $4,251,905.14. This trade represents a 20.96% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Jack Kaye sold 21,167 shares of uniQure stock in a transaction on Tuesday, June 30th. The shares were sold at an average price of $46.44, for a total value of $982,995.48. Following the completion of the sale, the director directly owned 25,996 shares of the company’s stock, valued at $1,207,254.24. This trade represents a 44.88% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 433,229 shares of company stock worth $17,944,799. Corporate insiders own 4.65% of the company’s stock.

uniQure Price Performance

Shares of QURE stock opened at $38.97 on Monday. uniQure N.V. has a 1 year low of $8.73 and a 1 year high of $71.50. The company has a current ratio of 10.40, a quick ratio of 10.40 and a debt-to-equity ratio of 0.33. The firm’s 50 day moving average is $35.94 and its 200-day moving average is $25.68. The firm has a market capitalization of $2.46 billion, a price-to-earnings ratio of -11.20 and a beta of 0.90.

uniQure (NASDAQ:QURE) last issued its quarterly earnings results on Tuesday, May 5th. The biotechnology company reported ($0.85) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.88) by $0.03. uniQure had a negative net margin of 1,154.42% and a negative return on equity of 145.81%. The business had revenue of $3.56 million during the quarter, compared to analyst estimates of $5.21 million. Sell-side analysts forecast that uniQure N.V. will post -3.56 EPS for the current fiscal year.

uniQure Profile

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.